Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Merkel Cell Carcinoma Treatment Market Research Report Information By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), By Treatment (Surgery, Radiation Therapy, Chemotherapy), By End-User (Hospitals & Clinics, Diagnostic Centers), and Region (North America, Europe, Asia-Pacific, and Rest of the World)‚ÄĒForecast till 2030

ID: MRFR/Pharma/3900-HCR | 90 Pages | Author: Rahul Gotadki| May 2024

Global Merkel Cell Carcinoma Treatment Market Research (MRFR Insights)

The Merkel Cell Carcinoma Treatment Market size is projected reach USD 4.2 billion at CAGR of 3.9% from 2022 to 2030. The very aggressive skin cancer Merkel Cell Carcinoma (MCC), also known as neuroendocrine carcinoma, is extremely uncommon (approximately forty times less likely to occur than the somewhat less uncommon and better-known malignant melanoma). The Merkel cell polyomavirus (MCPyV or MCV), which causes Merkel cell cancer, typically first manifests as a single, painless lump on sun-exposed skin. Although the particular cause of merkel cell carcinoma is unknown, those who have a history of other skin malignancies or excessive sun exposure, as well as people who are older and have low immune systems, are at higher risk of developing the disease. It is crucial to the healthcare industry, so it is predicted to grow significantly during the forecast period.

The market for merkel cell cancer therapies is expected to grow significantly throughout the projected period. After melanoma, Merkel cell carcinoma is the most lethal kind of skin cancer. Excessive sun exposure and immune system dysfunction are the primary causes of this cancer. Growth in the treatment of merkel cell cancer has been bolstered by positive reimbursement policies and robust use of immunotherapy. Rising cancer rates, improved access to healthcare, rising levels of ultraviolet radiation due to pollution and climate change, rising rates of immunosuppression, and rising numbers of newly diagnosed cancer patients all point to a bright future for the merkel cell carcinoma therapeutics market.

Growth in the global market for merchandising and distribution services is predicted to be driven by a number of factors, including rising spending on pharmaceuticals in developing countries, an increasing focus on "patient-centric" care that is expected to spur innovation regarding effective drugs and revolutionize technological advances in research and development, and significant unmet needs that are expected to encourage the emergence of a new market entrant and the widespread adoption of novel therapies.

August 2023: Clinical data from the Company's ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma will be presented in an abstract accepted by the American Society for Dermatologic Surgery in August 2023. Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Clinical and histological clearance of treated BCC lesions from the current Phase 2 study by the Company were emphasized at the announcement as evidence of the anticancer activity of VP-315.

COVID-19 Impact Analysis

All businesses have been significantly affected by the current Covid-19 outbreak. Medical aid was in short supply in the healthcare industry due to a lack of beds to meet the demands of the expanding patient population. The majority of businesses are inactive, and those located close to consumers' homes are barely able to handle sales, which is producing fluctuations in the global economy. The pandemic COVID-19 had a negative impact on the treatment of intestinal cancer, which can negatively affect patients' overall and disease-free survival. The number of referrals for intestinal cancer treatment has dramatically decreased as a result of the drop in COVID-19 patients.

Merkel Cell Carcinoma Treatment Market Dynamics

During the anticipated timeframe, there will likely be a significant expansion in the market for treatments for merkel cell cancer. Merkel cell carcinoma is the most common type of skin cancer after melanoma fatality after melanoma. A compromised immune system and excessive sun exposure are the main causes of this malignancy. Positive reimbursement and strong immunotherapy uptake are optimistic signs for merkel cell cancer treatment growth. The market for merkel cell carcinoma therapeutics is expected to expand due to a number of factors, including the rising incidence of cancer, better health insurance coverage, increased UV exposure from pollution and global warming, a higher prevalence of immunosuppression that causes more cancer cases, and increased research and development of therapeutics.

Market Drivers

  • The increasing incidence of merkel cell cancer

Among the major factors driving the worldwide market is the disease's increasing prevalence. An article in the Current Dermatology Reports journal estimated that MCC affects about 0.6 of every 100,000 people annually. According to the National Cancer Database, there are approximately 2500, and 1500 new MCC cases reported year in the US and European regions, respectively. The market is anticipated to grow as a result of expanding research and development efforts for the treatment of merkel cell carcinoma. Surgery is frequently used as the initial treatment for patients with merkel cell cancer.

Market Restraints:

  • The negative consequences of external radiation therapy will limit market expansion

External radiation therapy can, however, have certain negative side effects, such as skin changes, nausea, diarrhea, exhaustion, severe mouth and throat ulcers, and dry mouth or thick saliva. The radiation's negative effects are transient, but very rarely, major side effects can last a lifetime. Radiation to the chest can occasionally damage the lungs, which can cause breathing issues and shortness of breath

Market Opportunities:

  • The rise in investment in treatment

Increasing pharmaceutical investment from developing nations, a growing emphasis on "patient-centric" care, which is anticipated to foster innovation regarding effective drugs, revolutionize technological advancements in research and development, and high unmet needs, which is anticipated to lead to the entry of a new player and increase in acceptance of newer treatments, and technological advancements are all factors that are expected to propel the global market for merkel cell carcinoma treatment over the projected period.


Merkel Cell Carcinoma Treatment Market Segmentation

Segment Insights

Based on segment, the market has been divided into surgery, radiation therapy, and chemotherapy. The global market for merkel cell carcinoma treatment growth was prominently high under the radiation therapy segment held a major share in 2021. Due to clinical trials being conducted by the major players, radiation treatment is anticipated to grow in the market over the upcoming years. High doses of radiation are used in radiation therapy, also known as radiotherapy, as a cancer treatment to eradicate cancer cells and reduce tumor size. As with x-rays of teeth or fractured bones, radiation is utilized at low levels in x-rays to see within the body. Cancer cells are not quickly destroyed by radiation therapy. Days or weeks of treatment are needed before the DNA damage is sufficient to kill cancer cells. Cancer cells continue to die for a few weeks or months after radiation therapy is finished

Treatment Insights

Based on treatment, the Merkel Cell Carcinoma Treatment Market segment has been divided into surgery, radiation therapy, and chemotherapy. The global market growth was prominently high under the chemotherapy segment held a major share in 2021. The rise of the chemotherapy sector in the worldwide Merkel cell carcinoma treatments market is anticipated to be aided by doctors' preference for chemotherapy drugs in the treatment of cancer.

End-User Insights

Based on end-user, the Merkel Cell Carcinoma Treatment Market segmentation has been divided into hospitals & clinics, and diagnostic centers. The Merkel Cell Carcinoma Treatment Market growth was prominently high under the hospitals & clinics segment held a major share in 2021 because there are many facilities in one place and cutting-edge technology is readily available.Merkel Cell Carcinoma Market Share, by Region, 2021

March 2023: The FDA has approved Zynyz, an injectable medication developed by Incyte, in March 2023. The Merkel cell carcinoma (MCC) medication was approved by the FDA under the rapid approval procedure for the treatment of patients with metastatic disease or recurrent locally progressed disease. Zynyz is an immunotherapy that works by inhibiting the PD-1 checkpoint. Along with Merck & Co.'s PD-1 inhibitor Keytruda and Pfizer and Merck KGaA's PD-L1 aimed Bavencio, it is the eighth checkpoint inhibitor to receive FDA approval and the third intended for metastatic MCC. The POD1UM-201 trial provided the basis for the approval, as it was a single-arm evaluation of the medicine in adults who had never had systemic treatment before.

Merkel Cell Carcinoma Treatment Market Overview, by Region

By region, the Merkel Cell Carcinoma Treatment Market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the most extensive market share. Europe is projected to exhibit the highest CAGR during the review period.

North America

North America was the most extensive market for merkel cell carcinoma treatment share in 2021 due to the presence of advanced economies like the United States and Canada, a strong healthcare industry, and high per capita healthcare costs. Additionally, market growth is boosted by the presence of the leading industry players in the area.


Europe is anticipated to encounter the fastest growth rate during the forecast period. The availability of research funding, the sizeable patient population, and government backing for R&D are predicted to propel market expansion in the area. In addition, the rising number of skin cancer patients creates excellent conditions for market expansion in the area. 

Merkel Cell Carcinoma Treatment Market Competitive Landscape

The market includes tier-1, tier-2, and local players. The key market participants generally pursue the new market for merkel cell carcinoma treatment categories. In manufacturing, specialized robots programmed for a particular work environment are generally preferable to the market for merkel cell carcinoma treatment. Investment is anticipated to strengthen the company's leadership in market for merkel cell carcinoma treatment because more money is being invested in updating and replacing deteriorating grid infrastructure.

Key players in the Merkel Cell Carcinoma Treatment Market research include Merck & Co., OncoSec Medical Incorporated (U.S.), Bristol-Myers Squibb Company (U.S.), General Electric Company (U.S.), Siemens Medical Solutions USA CANON MEDICAL SYSTEMS CORPORATION, among others.

Scope of the Merkel Cell Carcinoma Treatment Market Report

Diagnosis Outlook

  • Physical Examination

  • Sentinel Node Biopsy

  • Imaging Test

Treatment Outlook

  • Surgery

  • Radiation Therapy

  • Chemotherapy

End-User Outlook

  • Cans

  • Pouches/Sachets

Region Outlook

  • North America

    • US

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia and New Zealand

    • Rest of Asia-Pacific

  • Rest of the World

    • South America

    • Middle East

    • Africa

Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

  • Merkel Cell Carcinoma Treatment Market¬†Forecast¬†& Size:

To identify and estimate the market size for the Merkel Cell Carcinoma Treatment Market report segmented by product, type, power rating and end-use by value (in US dollars). Also, to understand the consumption/ demand created by consumers of Merkel Cell Carcinoma Treatment Market forecast between 2022 and 2030

  • Market Landscape and Trends:

To identify the Merkel Cell Carcinoma Treatment Market growth and infer the drivers, restraints, opportunities, and challenges.

  • Market Influencing Factors:

To find out the factors which are affecting the Merkel Cell Carcinoma Treatment Market size

  • Impact of COVID-19:

To identify and understand the various factors involved in the market affected by the pandemic

  • Company Profiling:

To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company in the past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.

Intended Audience

  • Manufacturers

  • Raw material suppliers

  • Retailers, wholesalers, and distributors

  • Governments, associations, and industrial bodies

  • Investors and Trade Experts

Report Attribute/Metric Details
  Market Size   4.2 Billion : 2030
  CAGR   3.9%: 2030
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage    Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Diagnosis, by Treatment, by End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), OncoSec Medical Incorporated (U.S.), Bristol-Myers Squibb Company (U.S.), General Electric Company (U.S.), Siemens Medical Solutions USA, Inc. (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), Philips Health Care (The Netherlands), AstraZeneca
  Key Market Opportunities   high cost of therapeutics and related side effects, lack of awareness, and low per capita healthcare expenditures
  Key Market Drivers   growing geriatric population, and rising healthcare expenditure

Frequently Asked Questions (FAQ) :

The Merkel Cell Carcinoma Treatment Market forecast period is 2022 - 2030

The market is expected to register a CAGR of ~90% over the next 10 years, according to the Merkel Cell Carcinoma Treatment Market research.

Europe is expected to register the highest CAGR during 2022 - 2030

North America held the largest share in 2021

The market size is expected to be USD 4.2 billion by 2030.

Merck & Co., OncoSec Medical Incorporated (U.S.), Bristol-Myers Squibb Company (U.S.), General Electric Company (U.S.), Siemens Medical Solutions USA CANON MEDICAL SYSTEMS CORPORATION are the major companies operating in the global market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.